Coherus Oncology (CHRS) Net Income (2013 - 2026)

Coherus Oncology has disclosed Net Income across 14 years of filings, most recently posting -$20.6 million for Q2 2026.

• In Q2 2026, Net Income fell 106.93% year-over-year to -$20.6 million; the TTM figure through Jun 2026 stood at -$132.1 million (down 173.51% YoY), while the FY2025 annual figure was $206.5 million, up 180.01% from the prior year.
• Net Income came in at -$20.6 million for Q2 2026 at Coherus Oncology, up from -$38.3 million in the prior quarter.
• In the past five years, Net Income ranged from a high of $297.8 million in Q2 2025 to a low of -$96.1 million in Q1 2022.
• Average Net Income over 5 years is -$21.8 million, with a median of -$41.3 million recorded in 2023.
• The largest YoY upside for Net Income was 2404.52% in 2025 against a maximum downside of 230.49% in 2025.
• Over 5 years, Net Income stood at -$58.9 million in 2022, then slumped by 35.3% to -$79.7 million in 2023, then surged by 36.35% to -$50.7 million in 2024, then gained by 25.75% to -$37.6 million in 2025, then surged by 45.19% to -$20.6 million in 2026.
• Per Business Quant data, the three most recent Net Income figures were -$20.6 million in Q2 2026, -$38.3 million in Q1 2026, and -$37.6 million in Q4 2025.